PortfoliosLab logoPortfoliosLab logo
ARCT vs. AMPH
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ARCT vs. AMPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Amphastar Pharmaceuticals, Inc. (AMPH). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ARCT achieves a 23.98% return, which is significantly higher than AMPH's -32.34% return.


ARCT

1D
-0.65%
1M
-11.32%
YTD
23.98%
6M
15.33%
1Y
-41.54%
3Y*
-34.37%
5Y*
-24.38%
10Y*

AMPH

1D
-1.79%
1M
-20.32%
YTD
-32.34%
6M
-34.30%
1Y
-30.33%
3Y*
-27.06%
5Y*
-0.72%
10Y*
1.39%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ARCT vs. AMPH - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
ARCT
Arcturus Therapeutics Holdings Inc.
23.98%-63.88%-46.18%85.91%-54.17%-14.68%155.18%
AMPH
Amphastar Pharmaceuticals, Inc.
-32.34%-27.88%-39.97%120.74%20.31%15.81%25.77%

Correlation

The correlation between ARCT and AMPH is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.26

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.19

Correlation (All Time)
Calculated using the full available price history since Apr 17, 2020

0.19

Fundamentals

Market Cap

ARCT:

$216.00M

AMPH:

$841.82M

EPS

ARCT:

-$1.81

AMPH:

$1.67

PS Ratio

ARCT:

4.47

AMPH:

1.19

PB Ratio

ARCT:

1.13

AMPH:

1.09

Total Revenue (TTM)

ARCT:

$46.80M

AMPH:

$720.53M

Gross Profit (TTM)

ARCT:

$40.72M

AMPH:

$341.13M

EBITDA (TTM)

ARCT:

-$84.61M

AMPH:

$155.96M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ARCT vs. AMPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT
ARCT Risk / Return Rank: 2525
Overall Rank
ARCT Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
ARCT Sortino Ratio Rank: 2828
Sortino Ratio Rank
ARCT Omega Ratio Rank: 2828
Omega Ratio Rank
ARCT Calmar Ratio Rank: 2121
Calmar Ratio Rank
ARCT Martin Ratio Rank: 2626
Martin Ratio Rank

AMPH
AMPH Risk / Return Rank: 1515
Overall Rank
AMPH Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
AMPH Sortino Ratio Rank: 1919
Sortino Ratio Rank
AMPH Omega Ratio Rank: 1818
Omega Ratio Rank
AMPH Calmar Ratio Rank: 1616
Calmar Ratio Rank
AMPH Martin Ratio Rank: 88
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARCT vs. AMPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Amphastar Pharmaceuticals, Inc. (AMPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ARCTAMPHDifference

Sharpe ratio

Return per unit of total volatility

-0.45

-0.57

+0.12

Sortino ratio

Return per unit of downside risk

-0.08

-0.51

+0.43

Omega ratio

Gain probability vs. loss probability

0.99

0.92

+0.07

Calmar ratio

Return relative to maximum drawdown

-0.56

-0.67

+0.11

Martin ratio

Return relative to average drawdown

-0.79

-1.39

+0.60

ARCT vs. AMPH - Sharpe Ratio Comparison

The current ARCT Sharpe Ratio is -0.45, which is comparable to the AMPH Sharpe Ratio of -0.57. The chart below compares the historical Sharpe Ratios of ARCT and AMPH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ARCTAMPHDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.45

-0.57

+0.12

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.27

-0.02

-0.25

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.03

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.12

0.15

-0.27

Drawdowns

ARCT vs. AMPH - Drawdown Comparison

The maximum ARCT drawdown since its inception was -95.23%, which is greater than AMPH's maximum drawdown of -74.05%. Use the drawdown chart below to compare losses from any high point for ARCT and AMPH.


Loading charts...

Drawdown Indicators


ARCTAMPHDifference

Max Drawdown

Largest peak-to-trough decline

-95.23%

-74.05%

-21.18%

Max Drawdown (1Y)

Largest decline over 1 year

-74.53%

-45.25%

-29.28%

Max Drawdown (3Y)

Largest decline over 3 years

-86.71%

-74.05%

-12.66%

Max Drawdown (5Y)

Largest decline over 5 years

-89.87%

-74.05%

-15.82%

Max Drawdown (10Y)

Largest decline over 10 years

-74.05%

Current Drawdown

Current decline from peak

-93.85%

-72.12%

-21.73%

Average Drawdown

Average peak-to-trough decline

-72.98%

-23.98%

-49.00%

Ulcer Index

Depth and duration of drawdowns from previous peaks

52.77%

21.90%

+30.87%

Volatility

ARCT vs. AMPH - Volatility Comparison

The current volatility for Arcturus Therapeutics Holdings Inc. (ARCT) is 18.67%, while Amphastar Pharmaceuticals, Inc. (AMPH) has a volatility of 26.71%. This indicates that ARCT experiences smaller price fluctuations and is considered to be less risky than AMPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ARCTAMPHDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.67%

26.71%

-8.04%

Volatility (6M)

Calculated over the trailing 6-month period

40.13%

45.74%

-5.61%

Volatility (1Y)

Calculated over the trailing 1-year period

92.40%

53.42%

+38.98%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.77%

44.99%

+46.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

102.22%

42.65%

+59.57%

Dividends

ARCT vs. AMPH - Dividend Comparison

Neither ARCT nor AMPH has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ARCT vs. AMPH - Financials Comparison

This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Amphastar Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
2.06M
171.17M
(ARCT) Total Revenue
(AMPH) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ARCT and AMPH have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AMPH has higher volatility (26.71%) compared to ARCT (18.67%). In terms of maximum drawdown, ARCT dropped -95.23% vs AMPH's -74.05%.

ARCT currently has the higher Sharpe Ratio (-0.45 vs -0.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ARCT and AMPH

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer